Between The Lines: Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial

home / between-the-lines / between-the-lines-acalabrutinib-versus-ibrutinib-in-previously-treated-chronic-lymphocytic-leuke

Michael R. Bishop, MD, and Bruce B. Bank, MD, review results from the ELEVATE-RR noninferiority trial on acalabrutinib versus ibrutinib in CLL, and discuss the clinical implications of the findings.

Introduction and CLL Background

EP. 1: Introduction and CLL Background

Michael R. Bishop, MD;Bruce B. Bank, MD
May 16th 2022

Michael R. Bishop, MD, introduces the 2021 Journal of Clinical Oncology publication, “Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial” and invites Bruce B. Bank, MD, to comment on the typical patients with chronic lymphocytic leukemia (CLL) he sees in his clinical practice.

ELEVATE-RR Study Overview

EP. 2: ELEVATE-RR Study Overview

Michael R. Bishop, MD;Bruce B. Bank, MD
May 16th 2022

Dr Bishop reviews the ELEVATE-RR trial enrollment strategy.

Patient Characteristics in ELEVATE-RR

EP. 3: Patient Characteristics in ELEVATE-RR

Michael R. Bishop, MD;Bruce B. Bank, MD
May 24th 2022

Dr Bishop comments on the characteristics of the patients with CLL who were enrolled in the ELEVATE-RR trial.

ELEVATE-RR: Efficacy Data

EP. 4: ELEVATE-RR: Efficacy Data

Michael R. Bishop, MD;Bruce B. Bank, MD
May 24th 2022

Experts discuss efficacy data from the ELEVATE-RR trial on the Bruton tyrosine kinase inhibitors acalabrutinib vs ibrutinib.

ELEVATE-RR: Safety Data

EP. 5: ELEVATE-RR: Safety Data

Michael R. Bishop, MD;Bruce B. Bank, MD
June 2nd 2022

Drs Bishop and Bank discuss ELEVATE-RR safety data.

Key Takeaways and Clinical Implications

EP. 6: Key Takeaways and Clinical Implications

Michael R. Bishop, MD;Bruce B. Bank, MD
June 2nd 2022

Michael R. Bishop, MD, and Bruce B. Bank, MD, summarize key takeaways from the ELEVATE-RR study and discuss the clinical implications of using BTK inhibitors in patients with CLL.

Unmet Needs and Future Directions in CLL

EP. 7: Unmet Needs and Future Directions in CLL

Michael R. Bishop, MD;Bruce B. Bank, MD
June 2nd 2022

Drs Bishop and Bank close by outlining remaining unmet needs in CLL, emerging regimens, and hopes for the future of care.

Recap: Noninferiority Comparison of Acalabrutinib and Ibrutinib for Previously Treated CLL

EP. 8: Recap: Noninferiority Comparison of Acalabrutinib and Ibrutinib for Previously Treated CLL

ONCOLOGY Staff
August 28th 2022

Michael R. Bishop, MD, and Bruce B. Bank, MD, review results from the ELEVATE-RR noninferiority trial on acalabrutinib versus ibrutinib in CLL, and discuss the clinical implications of the findings.